The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosis

Neuroblastoma is a biologically and clinically heterogeneous pediatric malignancy that includes a high-risk subset for which new therapeutic agents are urgently required. As well as MYCN amplification, activating point mutations of ALK and NRAS are associated with high-risk and relapsing neuroblasto...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Lett
Auteurs principaux: Kollareddy, Madhu, Sherrard, Alice, Park, Ji Hyun, Szemes, Marianna, Gallacher, Kelli, Melegh, Zsombor, Oltean, Sebastian, Michaelis, Martin, Cinatl, Jindrich, Kaidi, Abderrahmane, Malik, Karim
Format: Artigo
Langue:Inglês
Publié: Elsevier Science Ireland 2017
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5542135/
https://ncbi.nlm.nih.gov/pubmed/28602975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.canlet.2017.05.027
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires